Robert Cannon, MD
Interventional Pain Medicine · Fayetteville, ARNPI 1104806702
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $13,330 of the $15,271 with a category attached, or 87.3%. AbbVie accounts for 94.0% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $12,732 and has fallen 98.2% since, to $227 in 2024. Among interventional pain medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $126.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Abbott$712
- Medtronic$120
- Pfizer$79
What the payments were for
- Speaking & faculty fees$13,33087%
- Travel & lodging$8536%
- Food & beverage$1,0887%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$14,183
How this compares
$15,271 in reported general payments places this provider in the 90th percentile of 29 interventional pain medicine providers in Arkansas.
See all interventional pain medicine providers in Arkansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 24 | $2,803 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 70 | $1,589 |
| Tramadol Hcl | 73 | $772 |
| Methadone Hcl | 40 | $660 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 24 | $435 |
| Oxycodone Hcl | 38 | $397 |
| Gabapentin | 35 | $361 |
| Morphine Sulfate ErMorphine Sulfate | 14 | $278 |
| Celecoxib | 18 | $216 |
| Clonazepam | 22 | $129 |
| Pregabalin | 13 | $123 |
| Tizanidine Hcl | 11 | $106 |
| Baclofen | 16 | $105 |
| Diazepam | 17 | $28 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Fayetteville
- Jared EnnisFayetteville$4K
- Jason HoltFayetteville$2K
- Sameer JainBryant$56K
- Ryan KrafftMountain Home$51K
- Amir QureshiLittle Rock$14K
- Brett WhatcottFort Smith$10K
- Mohammad EldeebFort Smith$9K
- Ahmed GhalebLittle Rock$7K
- Michael AdamsMena$6K
- Majid SaleemLittle Rock$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.